BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Prognosis
229 results:

  • 1. Construction and verification of a histone deacetylases-related prognostic signature model for colon cancer.
    Hao L; Lu W; Wu J; Chen Y; Xu D; Wang P
    Sci Rep; 2024 Apr; 14(1):8983. PubMed ID: 38637684
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Inhibition of autophagy-related protein 7 enhances anti-tumor immune response and improves efficacy of immune checkpoint blockade in microsatellite instability colorectal cancer.
    Zhang W; Chen L; Liu J; Chen B; Shi H; Chen H; Qi H; Wu Z; Mao X; Wang X; Huang Y; Li J; Yu Z; Zhong M; Wang T; Li Q
    J Exp Clin Cancer Res; 2024 Apr; 43(1):114. PubMed ID: 38627815
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.
    Pan QZ; Zhao JJ; Liu L; Zhang DS; Wang LP; Hu WW; Weng DS; Xu X; Li YZ; Tang Y; Zhang WH; Li JY; Zheng X; Wang QJ; Li YQ; Xiang T; Zhou L; Yang SN; Wu C; Huang RX; He J; Du WJ; Chen LJ; Wu YN; Xu B; Shen Q; Zhang Y; Jiang JT; Ren XB; Xia JC
    Signal Transduct Target Ther; 2024 Apr; 9(1):79. PubMed ID: 38565886
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Exploring the clinical significance of IL-38 correlation with pd-1, CTLA-4, and FOXP3 in colorectal cancer draining lymph nodes.
    Yuan L; Tan Z; Huang J; Chen F; Hambly BD; Bao S; Tao K
    Front Immunol; 2024; 15():1384548. PubMed ID: 38533512
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Intratumor tertiary lymphatic structure evaluation predicts the prognosis and immunotherapy response of patients with colorectal cancer.
    Feng H; Zhang S; Zhou Q; Han F; Du G; Wang L; Yang X; Zhang X; Yu W; Wei F; Hao X; Ren X; Zhao H
    Front Immunol; 2024; 15():1302903. PubMed ID: 38500886
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Intratumoral injection of interferon gamma promotes the efficacy of anti-pd1 treatment in colorectal cancer.
    Tang Y; Wei J; Ge X; Yu C; Lu W; Qian Y; Yang H; Fu D; Fang Y; Zhou X; Wang Z; Xiao Q; Ding K
    Cancer Lett; 2024 Apr; 588():216798. PubMed ID: 38467181
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. TMEM160 promotes tumor immune evasion and radiotherapy resistance via PD-L1 binding in colorectal cancer.
    Dai X; Wu Z; Ruan R; Chen J; Huang C; Lei W; Yao Y; Li L; Tang X; Xiong J; Feng M; Deng J
    Cell Commun Signal; 2024 Mar; 22(1):168. PubMed ID: 38454413
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-pd-1 therapy efficacy against colorectal cancer.
    Lv Q; Zhang Y; Gao W; Wang J; Hu Y; Yang H; Xie Y; Lv Y; Zhang H; Wu D; Hu L; Wang J
    Pharmacol Res; 2024 Apr; 202():107126. PubMed ID: 38432446
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Unveiling the immune symphony: decoding colorectal cancer metastasis through immune interactions.
    He R; Huang S; Lu J; Su L; Gao X; Chi H
    Front Immunol; 2024; 15():1362709. PubMed ID: 38415252
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Immune cell infiltrates in peritoneal metastases from colorectal cancer.
    Sundström P; Hogg S; Quiding Järbrink M; Bexe Lindskog E
    Front Immunol; 2024; 15():1347900. PubMed ID: 38384469
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Lipid core-shell nanoparticles co-deliver FOLFOX regimen and siPD-L1 for synergistic targeted cancer treatment.
    Cao W; Zhang X; Li R; Li Z; Lu A; Yu F; Sun L; Wang J; Wang Z; He H
    J Control Release; 2024 Apr; 368():52-65. PubMed ID: 38368946
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Progress of pd-1/PD-L1 inhibitor combination therapy in immune treatment for HER2-positive tumors.
    Zhao S; Qiu Y; Yuan M; Wang Z
    Eur J Clin Pharmacol; 2024 May; 80(5):625-638. PubMed ID: 38342825
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Development and verification of a combined immune- and cancer-associated fibroblast related prognostic signature for colon adenocarcinoma.
    Wei J; Ge X; Qian Y; Jiang K; Chen X; Lu W; Yang H; Fu D; Fang Y; Zhou X; Xiao Q; Tang Y; Ding K
    Front Immunol; 2024; 15():1291938. PubMed ID: 38312843
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Pan-cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours.
    Chen Y; Gao Z; Mohd-Ibrahim I; Yang H; Wu L; Fu Y; Deng Y
    Clin Transl Med; 2024 Feb; 14(2):e1543. PubMed ID: 38303608
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. scRNA-seq of colorectal cancer shows regional immune atlas with the function of CD20
    Ji L; Fu G; Huang M; Kao X; Zhu J; Dai Z; Chen Y; Li H; Zhou J; Chu X; Lei Z
    Cancer Lett; 2024 Mar; 584():216664. PubMed ID: 38253219
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Targeting the NAT10/NPM1 axis abrogates PD-L1 expression and improves the response to immune checkpoint blockade therapy.
    Qin G; Bai F; Hu H; Zhang J; Zhan W; Wu Z; Li J; Fu Y; Deng Y
    Mol Med; 2024 Jan; 30(1):13. PubMed ID: 38243170
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Role of stromal PD-L1 expression in colorectal liver metastasis.
    Takasu C; Morine Y; Yoshikawa K; Nakao T; Tokunaga T; Nishi M; Kashihara H; Wada Y; Yoshimoto T; Shimada M
    BMC Cancer; 2024 Jan; 24(1):97. PubMed ID: 38233811
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Transient receptor potential channels as predictive marker and potential indicator of chemoresistance in colon cancer.
    Hu W; Wartmann T; Strecker M; Perrakis A; Croner R; Szallasi A; Shi W; Kahlert UD
    Oncol Res; 2023; 32(1):227-239. PubMed ID: 38188686
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Dual role of CD73 as a signaling molecule and adenosine-generating enzyme in colorectal cancer progression and immune evasion.
    Lian W; Jiang D; Lin W; Jiang M; Zhang Y; Wang H; Zhao L
    Int J Biol Sci; 2024; 20(1):137-151. PubMed ID: 38164172
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Prognostic significance and immunological role of HPRT1 in human cancers.
    Lu Y; Chen R; Zhang H; Sun X; Li X; Yang M; Zhang X
    Biomol Biomed; 2024 Mar; 24(2):262-291. PubMed ID: 38159260
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 12.